- Drug resistence proteins and PFS in ovarian cancer patients2013 | Faculty of Medicine in Hradec Králové
- Retrospective study of patients with tubo-ovarian cancers (n = 510) and an analysis of main factors influencing PFS and OS – the experience of a comprehensive oncology center during 2010–20192022 | Faculty of Medicine in Pilsen
- End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Panitumumab in the treatment of colorectal carcinoma2020 | Publication without faculty affiliation
- Panitumumab as first-line treatment of colorectal cancer2019 | Publication without faculty affiliation
- Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib2014 | Faculty of Medicine in Pilsen
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | First Faculty of Medicine, Central Library of Charles University, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- The authors' own experience with axitinib in treating metastatic renal cell carcinoma2018 | First Faculty of Medicine
- Targeted therapy in metastatic melanoma2014 | Publication without faculty affiliation
- Evaluation of the MONARCH-2 trial2020 | Faculty of Medicine in Hradec Králové
- Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre2010 | First Faculty of Medicine
- Maintenance therapy with rituximab in patients with follicular lymphoma after 1 line treatment - PRIMA study2011 | Faculty of Medicine in Hradec Králové
- Cabazitaxel in the treatment of a patient with prostate cancer2020 | Publication without faculty affiliation
- Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic2021 | First Faculty of Medicine
- Axtinib in treatment metastatic renal cell carcinoma2016 | First Faculty of Medicine
- Long-term survival on vemurafenib monotherapy2017 | Publication without faculty affiliation
- Prognostic significance of survivin expression in patients with locally advanced rectal adenocarcinoma treated with postoperative adjuvant radiotherapy2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Treatment of Cervical Cancer with Paraaortic Lymph Node Involvement - Retrospective Review2020 | First Faculty of Medicine
- Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study2018 | First Faculty of Medicine
- Autologous transplantation in 495 multiple myeloma patients - Analysis from the Czech National Registry of Hematopoietic Stem Cell Transplantation2007 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Central Library of Charles University
- Chemoradiotherapy in the treatment of cervical cancer - a single institution retrospective review2022 | First Faculty of Medicine
- Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic2018 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Úspěšná léčba generalizovaného renálního karcinomu u osmdesátileté pacientky2017 | Publication without faculty affiliation
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Dabrafenib in the treatment of metastatic melanoma2014 | Publication without faculty affiliation
- Advances in immunotherapy of melanoma2016 | Publication without faculty affiliation
- VEGFREverolimus in the treatment of metastatic renal cell carcinoma - subanalysis of patients from the RECORD-1 study pretreated with one vs. two VEGFR inhibitors2012 | Second Faculty of Medicine
- Impact of BOLERO-2 study results on clinical practice and future treatment of postmenopausal patients with advance HR+/HER2- breast cancer2014 | First Faculty of Medicine
- Ribociclib2018 | First Faculty of Medicine
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
